SALT LAKE CITY — In this Healio Video Perspective from the ARVO meeting, Benjamin Bakall, MD, PhD, discusses 2-year data from the TEASE-1 study investigating the safety and efficacy of gildeuretinol in patients with Stargardt disease.
The study met its primary endpoint, and patients who received gildeuretinol (Alkeus Pharmaceuticals) showed a significant reduction in growth of the area of atrophy.
“As a retina specialist treating patients with Stargardt disease, it’s been very frustrating that we haven’t had any effective tools and options for treating the areas of